BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Remicade is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to reduce signs and symptoms of active ankylosing spondylitis. Remicade may be referred to by its drug name, infliximab.
Remicade is an immunomodulator, or in other words, a drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). Remicade is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Remicade is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
After initial loading doses, Remicade is administered every six or eight weeks by intravenous infusion.
Remicade is available in vial form.
The FDA-approved label for Remicade lists common side effects including infections (e.g. upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.
Rare but serious side effects listed for Remicade include serious bacterial, viral, and fungal infections, cancer, Hepatitis B, heart failure, blood disorders, allergic reactions, lupus-like syndrome, and demyelinating disease.
For more details about this treatment, visit:
Remicade — Janssen